Sandbox vidit: Difference between revisions
Jump to navigation
Jump to search
Line 9: | Line 9: | ||
:❑ Chronic heart failure | :❑ Chronic heart failure | ||
:❑ Hypotension | :❑ Hypotension | ||
:❑ Acute myocardial infarction <br> | :❑ Acute myocardial infarction <br> ❑ If present, treat as shown in the table below: | ||
<table class="wikitable"> | <table class="wikitable"> | ||
<tr><td>Conversion</td><td> DC cardioversion ([[ACC AHA guidelines classification scheme|class I, level of evidence C]])</td></tr> | |||
<tr><td>Conversion</td><td> DC cardioversion ([[ACC AHA guidelines classification scheme|class I, level of evidence C]]) | |||
<tr><td>Rate control</td><td>[[Beta blockers]] ([[ACC AHA guidelines classification scheme|class I, level of evidence C]])<br> or <br> [[Verapamil]] or [[diltiazem]] ([[ACC AHA guidelines classification scheme|class I, level of evidence A]])<br> or <br> [[Digitalis]] ([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]]) <br> or <br> [[Amiodarone]] ([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]])</td></tr> | <tr><td>Rate control</td><td>[[Beta blockers]] ([[ACC AHA guidelines classification scheme|class I, level of evidence C]])<br> or <br> [[Verapamil]] or [[diltiazem]] ([[ACC AHA guidelines classification scheme|class I, level of evidence A]])<br> or <br> [[Digitalis]] ([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]]) <br> or <br> [[Amiodarone]] ([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]])</td></tr> | ||
</table></div>|C02=<div style="float: left; text-align: left; padding:1em;"> ❑ Administer anticoagulation therapy based on the risk of stroke, if total duration of flutter > 48 hours <br> | </table></div>|C02=<div style="float: left; text-align: left; padding:1em;"> ❑ Administer anticoagulation therapy based on the risk of stroke, if total duration of flutter > 48 hours <br> Rate control therapy as shown in table below: | ||
<table class="wikitable"> | |||
<tr><td>Rate control</td><td>[[Beta blockers]] ([[ACC AHA guidelines classification scheme|class I, level of evidence C]])<br> or <br> [[Verapamil]] or [[diltiazem]] ([[ACC AHA guidelines classification scheme|class I, level of evidence A]])<br> or <br> [[Digitalis]] ([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]]) <br> or <br> [[Amiodarone]] ([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]])</td></tr> | |||
</table> <br><br> ''THEN'' <br><br> ❑ Attempt conversion as shown in table below: <br> | |||
<table class="wikitable"> | <table class="wikitable"> | ||
<tr><td>Conversion</td><td>Atrial or transesophageal pacing ([[ACC AHA guidelines classification scheme|class I, level of evidence A]])<br> or <br>DC cardioversion ([[ACC AHA guidelines classification scheme|class I, level of evidence C]])<br> or <br> Ibutilide ([[ACC AHA guidelines classification scheme|class IIa, level of evidence A]])<br> Flecainide ([[ACC AHA guidelines classification scheme|class IIb, level of evidence A]]) <br>Propafenone ([[ACC AHA guidelines classification scheme|class IIb, level of evidence A]]) <br> Sotalol ([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]]) <br> Procainamide ([[ACC AHA guidelines classification scheme|class IIb, level of evidence A]]) <br> Amiodarone ([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]]) </td></tr> | <tr><td>Conversion</td><td>Atrial or transesophageal pacing ([[ACC AHA guidelines classification scheme|class I, level of evidence A]])<br> or <br>DC cardioversion ([[ACC AHA guidelines classification scheme|class I, level of evidence C]])<br> or <br> Ibutilide ([[ACC AHA guidelines classification scheme|class IIa, level of evidence A]])<br> Flecainide ([[ACC AHA guidelines classification scheme|class IIb, level of evidence A]]) <br>Propafenone ([[ACC AHA guidelines classification scheme|class IIb, level of evidence A]]) <br> Sotalol ([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]]) <br> Procainamide ([[ACC AHA guidelines classification scheme|class IIb, level of evidence A]]) <br> Amiodarone ([[ACC AHA guidelines classification scheme|class IIb, level of evidence C]]) </td></tr> | ||
</table> </div> }} | </table> </div> }} | ||
{{familytree | | | |`|-|-|-|v|-|-|-|'| | | | | | | | }} | {{familytree | | | |`|-|-|-|v|-|-|-|'| | | | | | | | }} |
Revision as of 20:25, 11 March 2014
Therapeutic Approach
Shown below is an algorithm summarizing the therapeutic approach to atrial flutter.[1]
Atrial flutter | |||||||||||||||||||||||||||||||||||||||||||
Unstable | Stable | ||||||||||||||||||||||||||||||||||||||||||
❑ Look for the presence of any of these:
| ❑ Administer anticoagulation therapy based on the risk of stroke, if total duration of flutter > 48 hours Rate control therapy as shown in table below: THEN ❑ Attempt conversion as shown in table below:
| ||||||||||||||||||||||||||||||||||||||||||
❑ Assess need for therapy to prevent recurrence | |||||||||||||||||||||||||||||||||||||||||||
❑ Administer antiarrythmic therapy to prevent recurrences
❑ Consider catheter ablation if antiarrhythmic therapy fails | |||||||||||||||||||||||||||||||||||||||||||
- ↑ "ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias—Executive Summary". Retrieved 15 August 2013.